Literature DB >> 16353938

Kappa opioids as potential treatments for stimulant dependence.

Thomas E Prisinzano1, Kevin Tidgewell, Wayne W Harding.   

Abstract

Stimulant abuse is a major problem in the United States and the development of pharmacological treatments for stimulant abuse remains an important therapeutic goal. Classically, the "dopamine hypothesis" has been used to explain the development of addiction and dependence of stimulants. This hypothesis involves the direct increase of dopamine as the major factor in mediating the abuse effects. Therefore, most treatments have focused on directly influencing the dopamine system. Another approach, which has been explored for potential treatments of stimulant abuse, is the use of kappa opioid agonists. The kappa receptor is known to be involved, via indirect effects, in synaptic dopamine levels. This review covers several classes of kappa opioid ligands that have been explored for this purpose.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16353938      PMCID: PMC2751263          DOI: 10.1208/aapsj070361

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  123 in total

1.  U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking.

Authors:  S Schenk; B Partridge; T S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  1999-06       Impact factor: 4.530

Review 2.  Pharmacotherapies for treatment of cocaine abuse: preclinical aspects.

Authors:  F I Carroll; L L Howell; M J Kuhar
Journal:  J Med Chem       Date:  1999-07-29       Impact factor: 7.446

Review 3.  Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence.

Authors:  Ko Hasebe; Koji Kawai; Tomohiko Suzuki; Kuniaki Kawamura; Toshiaki Tanaka; Minoru Narita; Hiroshi Nagase; Tsutomu Suzuki
Journal:  Ann N Y Acad Sci       Date:  2004-10       Impact factor: 5.691

4.  Bremazocine reduces unrestricted free-choice ethanol self-administration in rats without affecting sucrose preference.

Authors:  P Nestby; A N Schoffelmeer; J R Homberg; G Wardeh; T J De Vries; A H Mulder; L J Vanderschuren
Journal:  Psychopharmacology (Berl)       Date:  1999-03       Impact factor: 4.530

5.  (+/-)Cyclazocine blocks the dopamine response to nicotine.

Authors:  I M Maisonneuve; S D Glick
Journal:  Neuroreport       Date:  1999-03-17       Impact factor: 1.837

Review 6.  U-50,488 and the kappa receptor: a personalized account covering the period 1973 to 1990.

Authors:  J Szmuszkovicz
Journal:  Prog Drug Res       Date:  1999

7.  Treatment of acute opioid withdrawal with ibogaine.

Authors:  K R Alper; H S Lotsof; G M Frenken; D J Luciano; J Bastiaans
Journal:  Am J Addict       Date:  1999

8.  Effects of the mixed-action kappa/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys.

Authors:  Glenn W Stevenson; Mark P Wentland; Jean M Bidlack; Nancy K Mello; S Stevens Negus
Journal:  Eur J Pharmacol       Date:  2004-12-15       Impact factor: 4.432

9.  Continuous infusion of selective dopamine uptake inhibitors or cocaine produces time-dependent changes in rat locomotor activity.

Authors:  S Izenwasser; D French; F I Carroll; P M Kunko
Journal:  Behav Brain Res       Date:  1999-03       Impact factor: 3.332

Review 10.  Tuberculosis: a search for novel therapy starting with natural products.

Authors:  L A Mitscher; W Baker
Journal:  Med Res Rev       Date:  1998-11       Impact factor: 12.944

View more
  26 in total

1.  N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: a Novel Class of Selective, Nonbasic, Nitrogen-Containing κ-Opioid Receptor Ligands.

Authors:  Kevin J Frankowski; Partha Ghosh; Vincent Setola; Thuy B Tran; Bryan L Roth; Jeffrey Aubé
Journal:  ACS Med Chem Lett       Date:  2010-08-12       Impact factor: 4.345

2.  The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats.

Authors:  Aashish S Morani; Amy Ewald; Katherine M Prevatt-Smith; Thomas E Prisinzano; Bronwyn M Kivell
Journal:  Eur J Pharmacol       Date:  2013-11-04       Impact factor: 4.432

Review 3.  The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.

Authors:  Sunmee Wee; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

Review 4.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

Review 5.  Novel medications to treat addictive disorders.

Authors:  Iván D Montoya; Frank Vocci
Journal:  Curr Psychiatry Rep       Date:  2008-10       Impact factor: 5.285

6.  Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A.

Authors:  Katherine M Prevatt-Smith; Kimberly M Lovell; Denise S Simpson; Victor W Day; Justin T Douglas; Peter Bosch; Christina M Dersch; Richard B Rothman; Bronwyn Kivell; Thomas E Prisinzano
Journal:  Medchemcomm       Date:  2011-12       Impact factor: 3.597

7.  Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.

Authors:  Mohini Ranganathan; Ashley Schnakenberg; Patrick D Skosnik; Bruce M Cohen; Brian Pittman; R Andrew Sewell; Deepak Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2012-07-18       Impact factor: 13.382

8.  Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy.

Authors:  Kevin J Frankowski; Michael P Hedrick; Palak Gosalia; Kelin Li; Shenghua Shi; David Whipple; Partha Ghosh; Thomas E Prisinzano; Frank J Schoenen; Ying Su; S Vasile; Eduard Sergienko; Wilson Gray; Santosh Hariharan; Loribelle Milan; Susanne Heynen-Genel; Arianna Mangravita-Novo; Michael Vicchiarelli; Layton H Smith; John M Streicher; Marc G Caron; Lawrence S Barak; Laura M Bohn; Thomas D Y Chung; Jeffrey Aubé
Journal:  ACS Chem Neurosci       Date:  2012-01-20       Impact factor: 4.418

9.  Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.

Authors:  C Austin Zamarripa; Jennifer E Naylor; Sally L Huskinson; E Andrew Townsend; Thomas E Prisinzano; Kevin B Freeman
Journal:  Psychopharmacology (Berl)       Date:  2020-01-31       Impact factor: 4.530

10.  Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors.

Authors:  Denise S Simpson; Kimberly M Lovell; Anthony Lozama; Nina Han; Victor W Day; Christina M Dersch; Richard B Rothman; Thomas E Prisinzano
Journal:  Org Biomol Chem       Date:  2009-07-14       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.